Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 58 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMACIE DEFRANCE from Jette, company number BE0887821796, closed financial year 2025 with a result of € 703 after tax. For that financial year PHARMACIE DEFRANCE recorded a gross margin of € 85,980 and equity of € -64,719. Compared with financial year 2024, the result moved from € 11,908 to € 703. The company is profitable. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ -64,719
▲ € 703 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 703
▼ 94% vs 2024
Profit after tax over the fiscal year.
€ 33,747
▲ 15% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -83,319.
People and assets in 2025
€ 79,612
▼ 37% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 40,800
€ 13,600 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 63,669
▲ 183% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 20,962
▼ 4% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 208,116 | € 96,355 | € 154,233 | € 85,980 | ▼ 44% |
| Profit after taxes | € 40,982 | € -45,171 | € 11,908 | € 703 | ▼ 94% |
| Equity | € -32,159 | € -77,330 | € -65,422 | € -64,719 | ▲ € 703 |
| Total debts | € 263,128 | € 246,004 | € 238,672 | € 293,923 | ▲ 23% |
| Cash | € 24,990 | € 21,978 | € 29,257 | € 33,747 | ▲ 15% |
| Land & buildings | € 4,392 | € 4,172 | € 3,952 | € 3,732 | ▼ 6% |
| Retained profit | € -50,759 | € -95,930 | € -84,022 | € -83,319 | ▲ € 703 |
| Bank debt | € 0 | € 0 | € 0 | € 40,800 | |
| Balance sheet total | € 230,969 | € 168,674 | € 173,250 | € 229,204 | ▲ 32% |
Key figures of PHARMACIE DEFRANCE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACIE DEFRANCE?
What happened at PHARMACIE DEFRANCE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 703 (▼ 94% vs 2024). Source: NBB ↗
- Medithera SA became a director. NBB
- Luc Defrance stepped down as director. NBB
- Brigitte Bienfait stepped down as director. NBB
- New establishment in Jette. KBO
- Start of the company according to the CBE. KBO
In short
From € 40,982 profit in 2022 to € 703 profit in 2025.
Paid € 2,014 in corporate taxes since 2022.
Best year ever: 2022, with € 40,982 profit.
A new publication or filing at PHARMACIE DEFRANCE? We notify you, reason included.
Follow PHARMACIE DEFRANCEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of MEDITHERA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMACIE DEFRANCEBehind PHARMACIE DEFRANCE is Medithera SA. The shares are held by MEDITHERA (100%).
Directors
According to the 2025 annual accounts
Director · represented by Philippe Seutin, Marc Seutin
since 2023
Luc Defrance
Director
· until 2023
Brigitte Bienfait
Director
· until 2023
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kardinaal Mercierplein 27
1090 Jette
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
HETZNER-AS, DE
Website info
Features
Security
Network
Details
- Company number
- 0887.821.796
- VAT number
- BE 0887.821.796
- Registered office
- Kardinaal Mercierplein 27, 1090 Jette
- Names & denominations
- PHARMACIE DEFRANCE
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 March 2007
- Peppol
- Active · Active since 7 Nov 2025
- Contact
- pharmaciecardinalmercier.be
- Activities · NACE
Apothekers
Detailhandel in farmaceutische producten